Organon & Co. (0A9W.IL)
IOB - IOB Delayed price. Currency in USD
Add to watchlist
At close: 07:02PM BST
| Previous close | 19.18 |
| Open | 19.87 |
| Bid | 0.00 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 19.54 - 20.25 |
| 52-week range | 10.89 - 24.05 |
| Volume | |
| Avg. volume | 2,750 |
| Market cap | 5.516B |
| Beta (5Y monthly) | 0.87 |
| PE ratio (TTM) | 6.76 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.12 (6.99%) |
| Ex-dividend date | 17 Aug 2023 |
| 1y target est | N/A |
- Business Wire
Organon Reports Results for the First Quarter Ended March 31, 2024
JERSEY CITY, N.J., May 02, 2024--Organon Reports Results for the First Quarter Ended March 31, 2024
- Business Wire
Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
JERSEY CITY, N.J., April 08, 2024--Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024
- Business Wire
Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints
SHANGHAI, China & JERSEY CITY, N.J., April 08, 2024--Organon and Henlius announce that Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoint
© 2024 Yahoo. All rights reserved.